Contributor Page
Potter Clarkson
 
Email  |  Articles
Contact Details
Tel: +44 44 115 955 2211
Fax: +44 44 115 955 2201
Park View House
58 The Ropewalk
Nottingham
NG1 5DD
UK
By Nick McDonald
To the surprise of many, the UK is expected to soon ratify the Unified Patent Court Agreement (UPCA), despite the 'Brexit' vote last June.
By John Peacock, Sanjay Kapur, Lucy Mills
The "investment function" was defined by the CJEU as "the use of the mark by its proprietor to acquire or preserve a reputation capable of attracting consumers and retaining their loyalty".
By John Miles, Ross Cummings, Michael Pears, Mike Snodin
The Court of Justice of the European Union (CJEU) ruled yesterday in an important case (C-125/10, Merck Sharp & Dohme Corp. v Deutsches Patent- und Markenamt), relating to Supplementary Protection Certificates (SPCs).
By John Miles, Michael Pears, Mike Snodin
Following hot on the heels of important SPC decisions issued in late 2011, the Court of Justice of the European Union (CJEU) has now issued a reasoned order in the Novartis v Actavis case (C-442/11).
By John Miles, Michael Pears, Mike Snodin
On 25 November 2011, the Court of Justice of the European Union (CJEU) decided three cases relating to Supplementary Protection Certificates (SPCs) by reasoned order (i.e. without a hearing).
By John Miles, Michael Pears, Mike Snodin
On 24 November 2011, the Court of Justice of the European Union (CJEU) delivered its judgement in two seminal cases relating to Supplementary Protection Certificates (SPCs).
By Ross Cummings
On 2 November 2011, the UK Supreme Court (formerly the House of Lords) handed down its decision in Human Genome Sciences Inc (HGS) v Eli Lilly and Company (Lilly), which was primarily concerned with the issue of industrial applicability of claimed biological material.